Pfizer shares rose 0.5% in premarket trading on Tuesday after the company reported first-quarter earnings and revenue that topped expectations. Pfizer also kept its full-year outlook unchanged, giving investors some reassurance as the company faces a tough period of patent expirations through the end of the decade.
Pfizer reported adjusted earnings of 75 cents per share, beating the analyst estimate of 72 cents. Revenue for the quarter reached $14.5 billion, above the $13.8 billion expected by Wall Street. The chief financial officer pointed to 22% operational revenue growth, thanks to new and acquired products. This suggests Pfizer’s efforts to expand its portfolio are starting to pay off.
Pfizer kept its full-year forecast for adjusted earnings at $2.80 to $3.00 per share and revenue between $59.5 billion and $62.5 billion, which matches what analysts expected. Management also said the outlook does not factor in any share buybacks in 2026.
This steady outlook comes as Pfizer faces a major period of patent expirations, with protections on important drugs like Eliquis ending before the decade is over. To address this, Pfizer is both working with generic drug makers to extend patents for some products, such as Vyndaqel, and expanding its pipeline through acquisitions and in-house development to make up for expected revenue losses from new competition.
